Education
About Us
Working with TipRanks
Follow Us
Solid Biosciences (SLDB)
NASDAQ:SLDB
SLDB Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.45 - $10.99
Previous CloseN/A
Volume1.97M
Average Volume (3M)1.30M
Market Cap
$284.40M
Enterprise Value$46.08M
Total Cash (Recent Filing)-$37.66M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta2.42
Next Earnings
May 08, 2025EPS Estimate
-0.56Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.04
Shares Outstanding77,492,960
10 Day Avg. Volume1,513,556
30 Day Avg. Volume1,296,663
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)370.16
Price to Cash Flow (P/CF)-3.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.16
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.37
Forecast
1Y Price Target
$17.13Price Target Upside366.76% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
---
Solid Biosciences News
See All SLDB News
---
Bulls Say, Bears Say
Bulls Say
Drug EfficacySGT-003 achieved a mean 90-day micro-dystrophin expression of 110% of normal measured by Western Blot, demonstrating the most robust micro-dystrophin expression among current DMD gene therapies.
Regulatory PathwaySLDB expects to dose more than 10 participants and plans to request meetings with the FDA to discuss potential accelerated approval pathways for SGT-003.
Safety ProfileThe drug was well tolerated with no serious adverse events or liver toxicity reported.
Bears Say
CompetitionRGX-202, but not SGT-003, requires the use of prophylactic eculizumab, which carries black box warnings and requires patient observation, further complicating gene therapy administration.
Price Target AdjustmentThe price target for SLDB has been adjusted from $28.00 to $20.00.
---
Ownership Overview
34.17% Insiders
2.87% Mutual Funds
34.96% Other Institutional Investors
22.77% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
SLDB FAQ
What was Solid Biosciences’s price range in the past 12 months?
Solid Biosciences lowest stock price was $2.45 and its highest was $10.99 in the past 12 months.
What is Solid Biosciences’s market cap?
Solid Biosciences’s market cap is $284.40M.
When is Solid Biosciences’s upcoming earnings report date?
Solid Biosciences’s upcoming earnings report date is May 08, 2025 which is in 12 days.
How were Solid Biosciences’s earnings last quarter?
Solid Biosciences released its earnings results on Mar 06, 2025. The company reported -$1 earnings per share for the quarter, missing the consensus estimate of -$0.805 by -$0.195.
Is Solid Biosciences overvalued?
According to Wall Street analysts Solid Biosciences’s price is currently Undervalued.
Does Solid Biosciences pay dividends?
Solid Biosciences does not currently pay dividends.
What is Solid Biosciences’s EPS estimate?
Solid Biosciences’s EPS estimate is -0.56.
How many shares outstanding does Solid Biosciences have?
Solid Biosciences has 77,492,960 shares outstanding.
What happened to Solid Biosciences’s price movement after its last earnings report?
Solid Biosciences reported an EPS of -$1 in its last earnings report, missing expectations of -$0.805. Following the earnings report the stock price went down -1.455%.
Which hedge fund is a major shareholder of Solid Biosciences?
Currently, no hedge funds are holding shares in SLDB
---
Solid Biosciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Price Target Potential
400.92% Upside
Analyst Consensus
Strong Buy
Average Price Target:
$17.13 (366.76% Upside)
$17.13 (366.76% Upside)
Blogger Sentiment
Bullish
SLDB Sentiment 75%
Sector Average 70%
Sector Average 70%
Insider Transactions
Bought Shares
Worth $22.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 2.9%
Last 30 Days ▼ 2.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-58.15%
12-Months-Change
Fundamentals
Return on Equity
-94.57%
Trailing 12-Months
Asset Growth
14.38%
Trailing 12-Months
Company Description
Solid Biosciences
Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candidate for the treatment of duchenne muscular dystrophy. It also engages in developing of platform technologies, including dual gene expression, a technology for packaging multiple transgenes into one vector, as well as novel capsids. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne Muscular Dystrophy. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
---
SLDB Stock 12 Month Forecast
Average Price Target
$17.13
▲(366.76% Upside)
Technical Analysis
Ocugen
―
Astria Therapeutics
―
iTeos Therapeutics
―
Compass Therapeutics
―
4D Molecular Therapeutics
―
Best Analysts Covering SLDB
1 Year
1 Year Success Rate
1/13 ratings generated profit
1 Year Average Return
-50.09%
reiterated a buy rating 2 months ago
Copying Gena Wang's trades and holding each position for 1 Year would result in 7.69% of your transactions generating a profit, with an average return of -50.09% per trade.
---